Filing Flows › Comparisons › PBLS vs SER
Parabilis Medicines vs Serina Therapeutics: PBLS and SER compared
Parabilis Medicines is the larger company: $148K of revenue in its latest quarter (Q2 2026) against $130K for Serina Therapeutics (Q2 2025).
Where the money goes: PBLS and SER
Parabilis Medicines (PBLS) · Q2 2026
Parabilis Medicines, Q2 2026: revenue $148K, net loss $52.5M. The chart follows the revenue to costs, profit and cash.
Serina Therapeutics (SER) · Q2 2025
Serina Therapeutics, Q2 2025: revenue $130K (+155% year over year), net loss $6.5M, operating cash flow −$3.8M. The chart follows the revenue to costs, profit and cash.
| Parabilis Medicines (PBLS) | Serina Therapeutics (SER) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2025 |
| Revenue | $148K | $130K |
| Revenue growth, Y/Y | — | +155% |
| Operating margin | n/m | n/m |
| Net earnings | −$52.5M | −$6.5M |
| Operating cash flow | — | −$3.8M |
Questions
Which is bigger, Parabilis Medicines or Serina Therapeutics?
Parabilis Medicines is the larger company: $148K of revenue in its latest quarter (Q2 2026) against $130K for Serina Therapeutics (Q2 2025).
More: Parabilis Medicines earnings · how Parabilis Medicines makes money · Serina Therapeutics earnings · how Serina Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 11, 2025). Fiscal quarters can end on different dates. Not investment advice.